BioSpace News Archive

ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced Dr Carl Firth, CEO, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 09:00 am ET.

BeyondSpring, a global pharmaceutical company focused on the development of cancer therapeutics, announced the positive topline data of DUBLIN-3 registrational trial in plinabulin in combination with docetaxel to treat 2nd and 3rd line NSCLC compared to docetaxel alone.

Bio-Techne Corporation announced that scientists at the U.S. Centers for Disease Control and Prevention recently highlighted the importance of fixed tissue analysis for retrospective diagnosis of SARS-CoV-2 infection and characterization of viral strains, particularly for fatal cases in which no previous testing for SARS-CoV-2 was performed.

Key Phase 3 milestones move tofersen, eplontersen and pelacarsen closer to the market Exclusive license to Bicycle Therapeutics’ technology potentially expands LICA technology capabilities Webcast , August 4, 2021, at 11:30 a.m. Eastern Time.

Elevation Oncology, Inc., a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced that Shawn M. Leland, PharmD, RPh, Founder and Chief Executive Officer of Elevation Oncology, will participate in a Targeted Oncology Panel at the 12th Annual Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021 at 10:20 a.m. ET.

Boston Scientific Corporation (NYSE: BSX) has commenced enrollment in the HI-PEITHO clinical trial, a collaborative research study with the Pulmonary Embolism Response Team (PERT) Consortium,

AVROBIO, Inc., a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 75,500 shares of the company’s common stock to five new employees as inducement awards under the company’s 2019 Inducement Plan.

ProMIS Neurosciences, Inc. issued today a Chairman’s memorandum, commenting on highlights of the recent 2021 Alzheimer’s Association International Conference (AAIC) with relevance to ProMIS and summarizing the ProMIS poster/oral presentation contributions to the meeting.

The only FDA-approved, ready-to-use oral solution for the acute treatment of migraine with or without aura in adults First step to building a growth platform in Neurology Patent protection until 2036

Inozyme Pharma, Inc. today announced Axel Bolte, MSc, MBA, the company’s co-founder, president, and chief executive officer, will participate in a panel at the 2021 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, Aug. 11.